103
Participants
Start Date
August 14, 2021
Primary Completion Date
January 23, 2024
Study Completion Date
July 19, 2024
Tenofovir Alafenamide
Administered as film-coated oral tablets
VIR-2218
Administered as a sub-cutaneous (SC) injection
Nivolumab
Administered intravenously
Selgantolimod
Administered as film-coated oral tablets
Auckland City Hospital, Grafton
Liverpool Hospital, Liverpool
Hvidovre Hospital, Hvidovre
Royal Melbourne Hospital, Parkville
Aarhus University Hospital, Aarhus N
Thai Red Cross AIDS Research Centre (HIV-NAT), Bangkok
Ramathibodi Hospital, Bangkok
Siriraj Hospital, Bangkok
Chiang Mai University, Maharaj Nakorn Chiang Mai Hospital, Muang
National University Hospital, Singapore
Changi General Hospital, Singapore
Aalborg University Hospital, Aalborg
Odense University Hospital, Odense
Princess Margaret Hospital (Hong Kong), Hong Kong
Queen Mary Hospital, Hong Kong
Prince of Wales Hospital, Shatin
Alice Ho Miu Ling Nethersole Hospital, Tai Po
Singapore General Hospital, Singapore
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Seoul Saint Mary Hospital, Seoul
Chung-Ang University Hospital, Seoul
Yonsei University Severance Hospital, Seoul
Korea University Guro Hospital, Seoul
King's College Hospital NHS Foundation Trust, London
Lead Sponsor
Vir Biotechnology, Inc.
INDUSTRY
Gilead Sciences
INDUSTRY